However in the treatment of MDD it is noteworthy that vortioxetine, a medication that combines serotonin reuptake inhibition with 5-HT1A receptor agonism, has beneficial effects on cognition in MDD (Mahableshwarkar et al. 2015; Bennabi et al. 2019) and to a greater extent than treatment with a selective serotonin reuptake inhibitor (SSRI) alone (Sagud et al. 2021). This evidence concerns the gene HTR1A and major depressive disorder.